Advertisement

Substantia nigra hyperechogenicity does not correlate with motor features in Parkinson's disease

Published:March 02, 2016DOI:https://doi.org/10.1016/j.jns.2016.03.002

      Highlights

      • Largest SN hyperechogenicity in PD patients did not correlate with UPDRS-III.
      • Side of the largest SN hyperechogenicity was not associated with affected body side.
      • Motor symptoms of PD were not associated with contralateral SN hyperechogenicity.

      Abstract

      Introduction

      The evaluation of hyperechogenicity of the substantia nigra (SN) by transcranial sonography (TCS) is validated for the diagnosis of Parkinson's disease (PD). However, its correlation with the severity of motor involvement is still uncertain.

      Methods

      We included patients with clinical diagnosis of idiopathic PD in a cross-sectional study. All patients were evaluated with Unified Parkinson's Disease Rating Scale-motor score (UPDRS-III) and TCS at the same day with measurement of the area of SN hyperechogenicity for each side. We analysed the association between the area of SN hyperechogenicity and the contralateral motor scores of UPDRS-III, adjusting for age and dominance of the patient (statistical significance set to p < 0.05).

      Results

      35 patients were analysed, 3 (8.6%) were excluded due to poor temporal acoustic bone window.
      From a total of 32 patients, the mean age was 58.4 (±11.2) years. The mean area of SN hyperechogenicity was: right 0.26 (±0.12) cm2 and left 0.27 (±0.07) cm2. The mean score of UPDRS-III was 18.9 (±6.1). There were no statistically significant association between the scores of the UPDRS-III (rigidity, tremor and bradykinesia) and the contralateral area of SN hyperechogenicity.

      Conclusion

      The area of SN hyperechogenicity did not correlate with motor deterioration in Parkinson's disease.

      Abbreviations:

      PD (Parkinson's disease), UPDRS-III (Unified Parkinson's disease rating scale-motor score), TCS (Transcranial sonography), SN (Substantia nigra), 123I-FP-CIT (123I-N-3-fluoropropyl-2beta-carbomethoxy-3beta-4-iodophenyl tropane)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Berardelli A.
        • Wenning G.K.
        • Antonini A.
        • et al.
        EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.
        Eur. J. Neurol. 2013; 20: 16-34
        • Movement Disorder Society Task Force on Rating Scales for Parkinson's D
        The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations.
        Mov. Disord. 2003; 18: 738-750
        • Lobsien E.
        • Schreiner S.
        • Plotkin M.
        • Kupsch A.
        • Schreiber S.J.
        • Doepp F.
        No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease.
        Mov. Disord. 2012; 27: 450-453
        • Doepp F.
        • Plotkin M.
        • Siegel L.
        • et al.
        Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor.
        Mov. Disord. 2008; 23: 405-410
        • Berg D.
        • Siefker C.
        • Becker G.
        Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings.
        J. Neurol. 2001; 248: 684-689
        • Spiegel J.
        • Hellwig D.
        • Mollers M.O.
        • et al.
        Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.
        Brain J. Neurol. 2006; 129: 1188-1193
        • Mehnert S.
        • Reuter I.
        • Schepp K.
        • Maaser P.
        • Stolz E.
        • Kaps M.
        Transcranial sonography for diagnosis of Parkinson's disease.
        BMC Neurol. 2010; 10: 9
        • Walter U.
        • Dressler D.
        • Wolters A.
        • Wittstock M.
        • Benecke R.
        Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease.
        Mov. Disord. 2007; 22: 48-54
        • Berg D.
        Five-Year Follow-Up Study of Hyperechogenicity of the Substantia Nigra in Parkinson's Disease.
        2005
        • Weise D.
        • Lorenz R.
        • Schliesser M.
        • Schirbel A.
        • Reiners K.
        • Classen J.
        Substantia nigra echogenicity: a structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
        Mov. Disord. 2009; 24: 1669-1675
        • Walter U.
        • Behnke S.
        • Eyding J.
        • et al.
        Transcranial brain parenchyma sonography in movement disorders: state of the art.
        Ultrasound Med. Biol. 2007; 33: 15-25
        • Stockner H.
        • Sojer M.
        • K K.S.
        • et al.
        Midbrain sonography in patients with essential tremor.
        Mov. Disord. 2007; 22: 414-417
        • Behnke S.
        • Runkel A.
        • Kassar H.A.
        • et al.
        Long-term course of substantia nigra hyperechogenicity in Parkinson's disease.
        Mov. Disord. 2013; 28: 455-459
        • Walter U.
        • Wittstock M.
        • Benecke R.
        • Dressler D.
        Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease.
        J. Neural. Transm. 2002; 109: 191-196
        • Schweitzer K.J.
        • Hilker R.
        • Walter U.
        • Burghaus L.
        • Berg D.
        Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.
        Mov. Disord. 2006; 21: 94-98
        • Gotz M.E.
        • Double K.
        • Gerlach M.
        • Youdim M.B.
        • Riederer P.
        The relevance of iron in the pathogenesis of Parkinson's disease.
        Ann. N. Y. Acad. Sci. 2004; 1012: 193-208
        • Berg D.
        • Roggendorf W.
        • Schroder U.
        • et al.
        Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.
        Arch. Neurol. 2002; 59: 999-1005
        • Oakley A.E.
        • Collingwood J.F.
        • Dobson J.
        • et al.
        Individual dopaminergic neurons show raised iron levels in Parkinson disease.
        Neurology. 2007; 68: 1820-1825
        • van der Hoorn A.
        • Burger H.
        • Leenders K.L.
        • de Jong B.M.
        Handedness correlates with the dominant Parkinson side: a systematic review and meta-analysis.
        Mov. Disord. 2012; 27: 206-210